West Pharmaceutical Services (WST) Stock Forecast & Price Target

$359.68 +5.97 (+1.69%)

Closing price 03:59 PM Eastern

Extended Trading

$359.67 -0.01 (0.00%)

As of 06:18 PM Eastern

Compare

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy

Based on 15 Analyst Ratings

Sell
0

Hold
2

Buy
13

Based on 15 Wall Street analysts who have issued ratings for West Pharmaceutical Services in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 2 have given a hold rating, 11 have given a buy rating, and 2 have given a strong buy rating for WST.

Consensus Price Target

$363.17
0.97% Upside

According to the 15 analysts' twelve-month price targets for West Pharmaceutical Services, the average price target is $363.17. The highest price target for WST is $447.00, while the lowest price target for WST is $295.00. The average price target represents a forecasted upside of 0.97% from the current price of $359.68.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for WST and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for West Pharmaceutical Services and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

WST Analyst Ratings Over Time

Type	Current Forecast 7/13/25 to 7/13/26	1 Month Ago 6/13/25 to 6/13/26	3 Months Ago 4/14/25 to 4/14/26	1 Year Ago 7/13/24 to 7/13/25
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$363.17	$340.09	$315.67	$320.00
Forecasted Upside	0.97% Upside	3.58% Upside	17.86% Upside	41.01% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Moderate Buy

WST Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

WST Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

West Pharmaceutical Services Stock vs. The Competition

Type	West Pharmaceutical Services	Medical Companies	Broader Market
Consensus Rating Score	3.00	2.30	2.52
Consensus Rating	Buy	Hold	Moderate Buy
Predicted Upside	1.15% Upside	730.71% Upside	13.75% Upside
News Sentiment Rating	Positive News See Recent WST News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/13/2026	BNP Paribas Exane 5 of 5 stars	Curtis Moiles Not Rated	Initiated Coverage	Outperform	$447.00	+26.38%
7/9/2026	Morgan Stanley 3 of 5 stars	Kallum Titchmarsh Not Rated	Boost Target	Equal Weight	$325.00 ➝ $365.00	+2.02%
7/6/2026	Evercore 3 of 5 stars		Reiterated Rating	Outperform	$410.00	+14.20%
7/2/2026	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Knight Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$350.00 ➝ $390.00	+6.84%
6/9/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$310.00 ➝ $400.00	+25.01%
6/2/2026	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Etoch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$360.00	+13.97%
6/1/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$375.00	+18.72%
5/13/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
4/27/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C-) ➝ Hold (C)
4/24/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
Your book attached (Ad) Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. Download the Safe Trade Options Formula book for free before access closes
2/13/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Sourbeer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$340.00	+37.98%
2/13/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Justin Bowers Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$315.00	+29.70%
2/10/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$295.00	+17.85%
10/29/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Buy
9/15/2025	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jamie Clark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$311.00	+20.67%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$350.00 ➝ $355.00	+8.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 09:14 PM ET.

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, July 10, 2026. Please send any questions or comments about these West Pharmaceutical Services pros and cons to contact@marketbeat.com.

West Pharmaceutical Services
Bull Case

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

The current stock price is around $320, reflecting a strong market position and investor confidence in the company's growth potential.
West Pharmaceutical Services, Inc. reported a significant year-over-year revenue increase of 21.0%, indicating robust demand for its products and services in the pharmaceutical and biotech sectors.
The company has a solid return on equity of 19.03%, showcasing effective management and profitability, which can be attractive to investors looking for strong financial performance.
With a low debt-to-equity ratio of 0.07, West Pharmaceutical Services, Inc. demonstrates a conservative approach to leverage, reducing financial risk and enhancing stability for investors.
The firm has set ambitious earnings guidance for FY 2026, projecting EPS between 8.400 and 8.750, which suggests confidence in future profitability and growth.

West Pharmaceutical Services
Bear Case

Investors should be bearish about investing in West Pharmaceutical Services, Inc. for these reasons:

The stock has a relatively high PE ratio of 44.93, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
Despite strong revenue growth, the price-to-earnings-growth (P/E/G) ratio of 2.76 suggests that the stock may not be a bargain, as it reflects high expectations for future growth that may not materialize.
The beta of 1.18 indicates that the stock is more volatile than the market, which could lead to larger price swings and increased risk for investors.
With a quick ratio of 2.04, while indicating good short-term liquidity, it may also suggest that the company is holding onto excess cash rather than reinvesting it for growth.
Market capitalization fluctuations, currently around $24 billion, can lead to uncertainty in stock performance, especially in a competitive industry like pharmaceuticals.

WST Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for West Pharmaceutical Services is $363.17, with a high forecast of $447.00 and a low forecast of $295.00.

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings, 11 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" WST shares.

According to analysts, West Pharmaceutical Services's stock has a predicted upside of 0.97% based on their 12-month stock forecasts.

Over the previous 90 days, West Pharmaceutical Services's stock had 4 upgrades and 1 downgrade by analysts.

West Pharmaceutical Services has been rated by research analysts at Barclays, BNP Paribas Exane, Citigroup, Evercore, KeyCorp, Morgan Stanley, Stephens, Weiss Ratings, Wolfe Research, and Zacks Research in the past 90 days.

Analysts like West Pharmaceutical Services more than other "medical" companies. The consensus rating for West Pharmaceutical Services is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how WST compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With West Pharmaceutical Services Recommendations

This page (NYSE:WST) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

WST Analyst Ratings Over Time

WST Analyst Recommendations By Month

WST Price Targets by Month

West Pharmaceutical Services Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

West Pharmaceutical Services
Bull Case

West Pharmaceutical Services
Bear Case

WST Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With West Pharmaceutical Services Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

WST Analyst Ratings Over Time

WST Analyst Recommendations By Month

WST Price Targets by Month

West Pharmaceutical Services Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy West Pharmaceutical Services Stock? WST Pros and Cons Explained

West Pharmaceutical Services Bull Case

West Pharmaceutical Services Bear Case

WST Forecast - Frequently Asked Questions

What is West Pharmaceutical Services' forecast for 2026?

Should I buy or sell West Pharmaceutical Services stock right now?

Does West Pharmaceutical Services's stock price have much upside?

Has West Pharmaceutical Services been upgraded or downgraded by Wall Street analysts recently?

What analysts cover West Pharmaceutical Services?

Do Wall Street analysts like West Pharmaceutical Services more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With West Pharmaceutical Services Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

West Pharmaceutical Services
Bull Case

West Pharmaceutical Services
Bear Case